ADA Scientific Sessions 2026 Abstract

Benefits of HR17031 vs. Insulin Glargine (iGlar) in Patients (pts) with Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) and Metformin

By Liming Chen, Qiumei Zhang, Nianrong Mi, Yang Xinfeng

Trial in peopleInterventions

The paper

Liming Chen, Qiumei Zhang, Nianrong Mi, Yang Xinfeng

Tianjin

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1712-P

doi.org/10.2337/db26-1712-p

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes